School mask policies and SARS-CoV-2 seroprevalence among school-age children-United States, September to December 2021

被引:0
|
作者
Nycz, Elise [1 ]
Deng, Yangyang [2 ]
Van Dyke, Miriam E. [1 ]
Bratcher, Anna [1 ]
Shi, Jianrong [1 ]
Iachan, Ronaldo [2 ]
Berney, Kevin [3 ]
Jones, Jefferson M. [1 ]
Clarke, Kristie E. N. [1 ]
机构
[1] CDCP, COVID 19 Response Team, Atlanta, GA 30333 USA
[2] Agcy Tox Subst & Dis Registry, ICF, Atlanta, GA USA
[3] Agcy Tox Subst & Dis Registry, Geospatial Res Anal & Serv Program GRASP, Atlanta, GA USA
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 10期
关键词
immunology; immunoserology; seroprevalence; SARS-CoV-2; masks; schools; pediatric infectious disease; public health; ELEMENTARY-SCHOOLS; TRANSMISSION; COUNTY; INFECTION;
D O I
10.1128/spectrum.00691-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
During September to December 2021, school mask policies to mitigate SARS-CoV-2 transmission varied throughout the US. We compared infection-induced seroprevalence estimates and estimated seroconversion among children residing in areas with and without school mask requirements. We estimated infection-induced seroprevalence among children in three age groups (5-17, 5-11, and 12-17 years) in areas with and without school district mask requirements for two time points: September 1-30, 2021 and December 15, 2021 to January 14, 2022. Robust Poisson regression models estimated population seroconversion over the semester among initially seronegative children. Permutation tests assessed for significant differences in the estimated population seroconversion due to incident infections by school district mask policy. Residing in an area with no school mask requirement was associated with higher infection-induced seroprevalence among children aged 5-17 years (adjusted prevalence ratio [aPR] = 1.18, 95% confidence interval [CI]: 1.10, 1.26), and those aged 5-11 years (aPR) = 1.21, 95% CI: 1.10, 1.32) and those aged 12-17 years (aPR = 1.16, 95% CI: 1.07, 1.26), compared with areas requiring masks in school. Estimated population seroconversion during the semester was also significantly higher among children in districts without mask policies than those with school mask requirements among all age groups (5-17 years: 23.7% vs 18.1%, P < 0.001; 5-11 years: 6.4% vs 4.5%, P = 0.002;12-17 years: 27.2% vs 21.0%, P < 0.001). During the U.S. Fall 2021 semester, areas with school mask requirements had lower infection-induced seroprevalence and an estimated lower proportion of seroconversion due to incident infection among school-aged children compared with areas without school mask requirements; causality cannot necessarily be inferred from these associations. IMPORTANCE During the U.S. Fall 2021 school semester, the estimated proportion of previously uninfected school-aged children who experienced a first infection with SARS-CoV-2 was lower in areas where public school district policies required masks for all staff and students compared with areas where the school districts had no mask requirements. Because children are more likely than adults to experience asymptomatic or mild SARS-CoV-2 infections, the presence of infection-induced antibodies is a more accurate measure of infection history than clinical testing. The proportion of children with these antibodies (i.e., seroprevalence) can improve our understanding of SARS-CoV-2 by detecting more infections and eliminating potential bias due to local testing and reporting practices. Enhanced robustness of surveillance for respiratory infections in children, including records of mitigation policies in communities and schools, as well as seroprevalence data, would establish a better evidence base for policy decisions and response measures during future respiratory outbreaks.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] An assessment of the vaccination of school-aged children in England against SARS-CoV-2
    Matt J. Keeling
    Sam E. Moore
    BMC Medicine, 20
  • [42] An assessment of the vaccination of school-aged children in England against SARS-CoV-2
    Keeling, Matt J.
    Moore, Sam E.
    BMC MEDICINE, 2022, 20 (01)
  • [43] Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021
    Eric Lyimo
    Cyrielle Fougeroux
    Anangisye Malabeja
    Joyce Mbwana
    Paul M. Hayuma
    Edwin Liheluka
    Louise Turner
    Samwel Gesase
    Thomas Lavstsen
    John P. A. Lusingu
    Daniel T. R. Minja
    Christian W. Wang
    BMC Infectious Diseases, 22
  • [44] High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020-March 2021
    Iwamoto, Chelsea
    Lesteberg, Kelsey E.
    Lamb, Molly M.
    Calvimontes, Diva M.
    Guo, Kejun
    Barrett, Bradley S.
    Mickens, Kaylee L.
    Duca, Lindsey M.
    Monzon, Jose
    Chard, Anna N.
    Guzman, Gerber
    Barrios, Edgar
    Rojop, Neudy
    Arias, Kareen
    Gomez, Melissa
    Paiz, Claudia
    Bolanos, Guillermo Antonio
    Edwards, Kathryn M.
    Gutierrez, Emily Zielinski
    Azziz-Baumgartner, Eduardo
    Asturias, Edwin J.
    Santiago, Mario L.
    Beckham, J. David
    Olson, Daniel
    VACCINES, 2022, 10 (07)
  • [45] Seroprevalence of anti-SARS-CoV-2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada
    Zinszer, Kate
    McKinnon, Britt
    Bourque, Noemie
    Zahreddine, Monica
    Charland, Katia
    Papenburg, Jesse
    Fortin, Genevieve
    Hamelin, Marie-Eve
    Saucier, Adrien
    Apostolatos, Alex
    Pierce, Laura
    Savard-Lamothe, Ashley
    Carbonneau, Julie
    Conrod, Patricia
    Haley, Nancy
    Laurin, Isabelle
    Boivin, Guy
    De Serres, Gaston
    Quach, Caroline
    BMJ OPEN, 2021, 11 (07):
  • [46] SARS-CoV-2 Seroprevalence in Delhi, India, During September-October 2021: A Population-Based Seroepidemiological Study
    Sharma, Pragya
    Basu, Saurav
    Mishra, Suruchi
    Gupta, Ekta
    Agarwal, Reshu
    Kale, Pratibha
    Mundeja, Nutan
    Charan, Bs
    Singh, Gautam
    Singh, Mongjam
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [47] Pens down: An outbreak of the B.1.617.2 SARS-CoV-2 variant in an Australian high school, August 2021
    Allen, Keeley
    Marmor, Alexandra
    Pourmarzi, Davoud
    COMMUNICABLE DISEASES INTELLIGENCE, 2022, 46
  • [48] Investigation of the seroprevalence to equine coronavirus and SARS-CoV-2 in healthy adult horses recently imported to the United States
    Pusterla, Nicola
    Lawton, Kaila
    Barnum, Samantha
    VETERINARY QUARTERLY, 2024, 44 (01) : 1 - 6
  • [49] Prevalence of SARS-CoV-2 infection among US blood donors by industry, May-December 2021
    Shi, Dallas S.
    Mcdonald, Emily
    Shah, Melisa
    Groenewold, Matthew R.
    Haynes, James M.
    Spencer, Bryan R.
    Stramer, Susan
    Feldstein, Leora R.
    Saydah, Sharon
    Jones, Jefferson
    Chiu, Sophia K.
    Rinsky, Jessica L.
    AMERICAN JOURNAL OF INDUSTRIAL MEDICINE, 2024, 67 (02) : 169 - 173
  • [50] Characteristics of healthcare personnel with SARS-CoV-2 infection: 10 emerging infections program sites in the United States, April 2020-December 2021
    Chea, Nora
    Eure, Taniece
    Ramirez, Rebecca Alkis
    Zlotorzynska, Maria
    Blazek, Gregory T.
    Nadle, Joelle
    Lee, Jane
    Czaja, Christopher A.
    Johnston, Helen
    Barter, Devra
    Kellogg, Melissa
    Emanuel, Catherine
    Meek, James
    Brackney, Monica
    Carswell, Stacy
    Thomas, Stepy
    Fridkin, Scott K.
    Wilson, Lucy E.
    Perlmutter, Rebecca
    Marceaux-Galli, Kaytlynn
    Fell, Ashley
    Lovett, Sara
    Lim, Sarah
    Lynfield, Ruth
    Shrum Davis, Sarah
    Phipps, Erin C.
    Sievers, Marla
    Dumyati, Ghinwa
    Myers, Christopher
    Hurley, Christine
    Licherdell, Erin
    Pierce, Rebecca
    Ocampo, Valerie L. S.
    Hall, Eric W.
    Wilson, Christopher
    Adre, Cullen
    Kirtz, Erika
    Markus, Tiffanie M.
    Billings, Kathryn
    Plumb, Ian D.
    Abedi, Glen R.
    James-Gist, Jade
    Magill, Shelley S.
    Grigg, Cheri T.
    INFECTION CONTROL & HOSPITAL EPIDEMIOLOGY, 2024, 45 (09) : 1090 - 1098